ROTFL. Three treated. One discharged. Two in early stage rehab. Statistically meaningless results, An absolute joke announcement.
These drugs (synthetic melanocortins) have been around for over 50 years years. There has been a huge amount of hype about treating a very wide range of medical conditions. But decades of clinical trials have had very little success. They have an extremely high rate (>10%) of unpleasant side effects. The only practical use found so far is creating sunless tans (that is how Scenesse actually 'treats' EPP). That is why Big Pharma has shown almost no interest in them.
- Forums
- ASX - By Stock
- CUV
- Ann: Afamelanotide well tolerated by first stroke patients
Ann: Afamelanotide well tolerated by first stroke patients, page-8
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.55 |
Change
-0.170(1.15%) |
Mkt cap ! $728.6M |
Open | High | Low | Value | Volume |
$15.00 | $15.00 | $14.27 | $1.051M | 72.59K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 293 | $14.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.59 | 293 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 293 | 14.400 |
1 | 293 | 14.370 |
1 | 293 | 14.350 |
1 | 293 | 14.320 |
3 | 1582 | 14.290 |
Price($) | Vol. | No. |
---|---|---|
14.590 | 293 | 1 |
14.610 | 293 | 1 |
14.640 | 293 | 1 |
14.670 | 1584 | 4 |
14.950 | 500 | 1 |
Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |